[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"hbv-hepatitis-b-virus\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:hbv-hepatitis-b-virus":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,46,82,104,127,154,178,205],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":29,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100595343","hivhbvhcv-triple-screening-in-primary-care-100595343",false,"NCT07031219","HIV\u002FHBV\u002FHCV Triple Screening in Primary Care","Syndemic Triple HIV\u002FHBV\u002FHCV Virus Screening Via EMR Automation at Primary Care Clinics","Inclusion Criteria:\n\n* Outpatient primary care adult providers at participating institutions\n* Providers who provide consent to participate in this study.\n* Providers must intend to continue their current practice for at least 12 months.\n* Providers with at least 12 months experience in their current practice.\n\nExclusion Criteria:\n\n* Providers who do not consent to participate\n* Sub-specialty providers\n* Pediatric providers\n* Providers who anticipate leaving their current practice within the next 12 months (i.e. providers who plan to retire, move, etc.).\n* Providers with less than 12 months experience in their current practice (i.e. new providers or trainees who joined the practice within the last year)\n* Note: family medicine and med\u002Fpeds providers can participate, but only for their adult patients. The intervention alert+order panel and any data collection will be restricted to adult patients ≥ 18 years old.","ALL","18 Years",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Design:\n\nThis will be a within-subjects repeated-measures design, testing an electronic medical record pop-up alert linked to order panels for screening blood tests for human immunodeficiency virus (HIV), hepatitis B virus (HBV), and hepatitis C virus (HCV). Study participants will be primary care providers. For each participating provider, their encounter will be randomized to either control (no alert; no changes to EMR interface) or an alert with triple-testing order panel intervention arm (alert linked to order panel with screening tests for all three bloodborne viruses (BBVs) selected by default; the alert will be triggered when a provider attempts to order a screening test for at least one BBV). The alert linked to triple testing orders will only be triggered if the provider orders a virus BBV screening test based on their normal practice and standard of care for their patient. Providers will see which orders are selected prior to signing (finalizing) them; therefore, this study will be unblinded. To mitigate the effect of unblinding, randomization will occur at the encounter level which will lead to providers experiencing both the control and intervention conditions randomly throughout the duration of the study.\n\nOutcomes\u002Fendpoints:\n\nThe investigators will compare incidences of HIV, HBV, and HCV diagnoses between the two encounter conditions, estimate number of cases missed by not triple-testing, estimate laboratory costs per condition, and measure patient encounters per condition.",[26,27,28],"HIV","HBV (Hepatitis B Virus)","HCV",[30,31,32],"screening","provider orders","quality improvement","NOT_YET_RECRUITING","2026-04-27",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":20},"2026-06-01",{"date":41,"type":20},"2027-06",{"name":43,"class":44},"University of Texas Southwestern Medical Center","OTHER",1,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":54,"sex":55,"minAge":4,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":69,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":73,"lastUpdatePostDateStruct":74,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":4},"100622850","magia-h3s-point-of-care-test-performance-for-hiv-hbv-hcv-and-syphilis-screening-in-pregnant-women-in-dr-congo-100622850","NCT07388979","MAGIA H3S Point of Care Test Performance for HIV, HBV, HCV, and Syphilis Screening in Pregnant Women in DR Congo","MAGIa In-vitro- Diagnostics Medical Device Dedicated to Combined Screening of HIV, HBV, HCV and Syphilis and HBV Reflective Panels aMong Congolese pregnAnt woMen Attending to Ante Natal Care Consultations","MAGICS MAM","Inclusion Criteria:\n\n* Being pregnant, regardless of age or stage of pregnancy (prenatal period);\n* Having signed an informed consent form at the start of prenatal care (CPN) to participate in the study.\n\nNote: for pregnant minors, the consent of a parent or legal guardian is required;\n\n* Have chosen to attend prenatal care at the healthcare facility selected for the study;\n* Plan to give birth at the same healthcare facility where they were included in the study;\n* Plan to attend postnatal care (PNC) and preschool consultations (PSC) at the same healthcare facility where they were included in the study.\n* Plan to give birth at the same health facility where they were enrolled;\n* Plan to attend postnatal consultations (PNC) and preschool consultations (PSC) at the same facility\n\nExclusion Criteria:\n\n* Women in labor or who refuse to give their consent.",true,"FEMALE",{"count":57,"type":20},7500,"12 Months","OBSERVATIONAL","Performance study to evaluate the clinical performance of the In-Vitro Diagnostic Medical Device MagIA H3S (a Multiplex Point-of-Care test for the combined detection of Human Immunodeficiency Virus (HIV), Hepatitis B and C and Syphilis) from pregnant women attending antenatal care (ANC) services in the Democratic Republic of the Congo. This study aligns with the WHO 2022-2030 strategy for the integrated elimination of mother-to-child transmission of HIV, HBV, HCV, and syphilis.",[62,27,63,64,65,66,67,68],"HIV - Human Immunodeficiency Virus","Hepatitis C Virus (HCV)","Syphilis","Mother-to-Child Transmission","Performance","Point of Care STI Testing","TREAT B",[70,71,72],"Triple elimination","Mother-to-child transmission","Democratic republic of the Congo","2026-01-28",{"date":75,"type":37},"2026-02-05",{"date":77,"type":20},"2026-03-01",{"date":79,"type":20},"2027-12-21",{"name":81,"class":44},"Gardiens de Vies",{"id":83,"slug":84,"hasResults":11,"nctId":85,"briefTitle":86,"officialTitle":86,"acronym":4,"eligibilityCriteria":87,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":88,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":90,"conditions":91,"keywords":4,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":45},"100614127","analysis-of-methylomic-features-and-prognostic-risk-prediction-in-patients-with-hepatitis-b-related-acute-on-chronic-liver-failure-100614127","NCT07275554","Analysis of Methylomic Features and Prognostic Risk Prediction in Patients With Hepatitis B-related Acute-on-chronic Liver Failure","Inclusion Criteria:\n\n* Chronic hepatitis B was persistent hepatitis B surface antigen (HBsAg) seropositivity for more than six months.\n\nHepatitis B-related liver cirrhosis was diagnosed based on histological examination, typical features on ultrasound or radiological imaging, endoscopic findings of portal hypertension, and clinical history.\n\nHepatitis B-related acute-on-chronic liver failure meets the diagnostic criteria of the 2018 Asia-Pacific guidelines for the diagnosis and treatment of liver failure.Laboratory tests:Jaundice: Serum total bilirubin ≥ 85 µmol\u002FL and coagulopathy \\[International Normalized Ratio (INR) ≥ 1.5 or Prothrombin Activity (PTA) \\\u003C 40%\\].\n\nExclusion Criteria:\n\n* co-infection with other hepatitis viruses; history of hepatocellular carcinoma or other malignancies; concomitant autoimmune liver disease; or insufficient clinical data.",{"count":89,"type":20},100,"This study aims to investigate the methylomic features of patients with hepatitis B-related acute-on-chronic liver failure and establish and validate a prognostic risk prediction classification model. The findings are of significant importance for guiding clinical practice and improving patient prognosis. Additionally, a methylomics-based classifier model for liver failure will be developed for disease prognosis analysis and clinical assessment, with the potential to enhance the diagnostic efficiency of liver failure.",[92,93,27],"HBV Related Acute-on-chronic Liver Failure","HBV-related Liver Cirrhosis","RECRUITING","2025-11-27",{"date":97,"type":37},"2025-12-10",{"date":99,"type":37},"2024-12-31",{"date":101,"type":20},"2026-12-31",{"name":103,"class":44},"Qilu Hospital of Shandong University",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":54,"sex":16,"minAge":17,"maxAge":111,"enrollmentInfo":112,"targetDuration":114,"studyType":59,"phases":4,"briefSummary":115,"conditions":116,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":118,"lastUpdatePostDateStruct":119,"startDateStruct":121,"completionDateStruct":123,"leadSponsor":125,"locationsCount":4},"100611544","hepatitis-b-and-c-within-the-chinese-community-in-milan-100611544","NCT07241962","Hepatitis B and C Within the Chinese Community in Milan","Prevalence of Hepatitis B and C Within the Chinese Community Residing in Milan","Inclusion Criteria:\n\n* Adults aged 18 to 50 years\n* Self-identified as part of the Chinese community residing in Milan\n* Willing and able to provide informed consent\n* Willing to undergo HBV and\u002For HCV rapid screening (capillary blood test)\n* Able to complete an anonymous questionnaire on demographics, risk factors and awareness of HBV and HCV infections\n* Able to communicate in Italian or Chinese (with interpreter assistance, if needed)\n\nExclusion Criteria:\n\n* Age under 18 or over 50 years\n* Not from the Chinese community or not residing in Milan\n* Unable to provide informed consent\n* Currently undergoing treatment for HBV or HCV, or with previously confirmed diagnosis of HBV or HCV\n* Severe mental or physical illness impairing participation or understanding of consent\n* Unable to respond to the questionnaire, even with interpreter assistance\n* Pregnant women","50 Years",{"count":113,"type":20},1000,"1 Day","The goal of this observational study is to assess the effectiveness of targeted screening for Hepatitis B (HBV) and Hepatitis C (HCV) infections in adults aged 18 to 50 from the Chinese community residing in Milan.\n\nThe main questions it aims to answer are:\n\n* Does community-based, culturally sensitive screening increase the detection of undiagnosed HBV and HCV infections in this high-risk population?\n* What is the level of adherence, satisfaction and awareness regarding rapid testing methods in this community?\n\nParticipants will:\n\n* Receive pre-test counseling in Italian or Chinese with the help of an interpreter\n* Complete a brief, anonymous questionnaire on demographics, risk factors and awareness of HBV\u002FHCV\n* Undergo capillary rapid testing for HBV and\u002For HCV\n* Receive test results during the same visit\n* Complete a short post-test satisfaction questionnaire\n\nThe study will be conducted in public spaces within Milan's Chinatown, during monthly sessions, until 1,000 participants are enrolled. Each session will last approximately 30-60 minutes per participant.",[27,117],"HCV Infection","2025-11-17",{"date":120,"type":37},"2025-11-21",{"date":122,"type":20},"2025-12",{"date":124,"type":20},"2026-12",{"name":126,"class":44},"IRCCS Ospedale San Raffaele",{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":131,"acronym":4,"eligibilityCriteria":132,"healthyVolunteers":11,"sex":16,"minAge":133,"maxAge":134,"enrollmentInfo":135,"targetDuration":137,"studyType":59,"phases":4,"briefSummary":138,"conditions":139,"keywords":142,"overallStatus":94,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":45},"100603494","immune-dynamics-in-the-natural-history-of-chronic-hbv-infection-100603494","NCT07137247","Immune Dynamics in the Natural History of Chronic HBV Infection","Inclusion Criteria:\n\n* Aged 1-80 years, either male or female.\n* Patients diagnosed with chronic hepatitis B virus infection in accordance with the \"Guidelines for the Prevention and Treatment of Chronic Hepatitis B\" (2019 edition).\n* No antiviral treatment (including nucleoside analogs and interferons, etc.) within the past six months.\n\nExclusion Criteria:\n\n• Concurrent Infections and Liver Diseases: Exclusion of patients with concurrent HCV or HIV infection, alcoholic fatty liver disease, non-alcoholic fatty liver disease, autoimmune liver diseases.\n\n• Immune and Coagulation System Disorders: Exclusion of patients with immune system diseases such as hyperthyroidism, coagulation system disorders such as diabetes mellitus or idiopathic thrombocytopenic purpura.\n\n* Severe Underlying Diseases. Exclusion of patients with severe underlying diseases that affect the body's immune status.\n* Other Unsuitable Conditions:\n\nExclusion of patients whom the investigator deems to have other conditions that make them unsuitable for enrollment.","1 Year","80 Years",{"count":136,"type":20},5000,"3 Years","The purpose of this observational study is to follow up on chronic HBV-infected patients over a long period of time to understand the changes in the immune status as age increases and the natural history of chronic HBV infection progresses. The main questions it aims to answer are:\n\n* Does the natural history of chronic HBV infection progress with changes in HBV-specific immunity?\n* What is the role of age in the natural history of chronic HBV infection?\n\nPatients with chronic HBV infection who are untreated and aged 1-80 years will be followed up every six months. During each follow-up, HBV-related serological and virological indicators will be tested. Peripheral blood samples will also be collected to test HBV-specific immunity and the immune environment.",[27,140,141],"HBV Infection","Chronic Hep B",[143,141,144],"HBV","HBV infection","2025-09-28",{"date":147,"type":37},"2025-09-30",{"date":149,"type":37},"2024-02-01",{"date":151,"type":20},"2041-12-01",{"name":153,"class":44},"Nanfang Hospital, Southern Medical University",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":143,"eligibilityCriteria":160,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":21,"phases":164,"briefSummary":166,"conditions":167,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":169,"lastUpdatePostDateStruct":170,"startDateStruct":172,"completionDateStruct":174,"leadSponsor":176,"locationsCount":4},"100604111","phase-2-zinc-sulphate-in-treatment-fibrosis-in-hbv-patient-receiving-antiviral-therapy-100604111","NCT07145268","Zinc Sulphate in Treatment Fibrosis in HBV Patient Receiving Antiviral Therapy","Clinical Study to Evaluate the Possible Antifibrotic Effect of Zinc Sulphate in Chronic HBV Patient Receiving Anti Viral Therapy","Inclusion Criteria:\n\n* Patients with fibrosis stage (F2\\&F3) post chronic HBV infection receiving standard antiviral therapy.\n* Age \\> 18 and \\\u003C 65 years.\n\nExclusion Criteria:\n\n* Patients with prior history of liver transplantation.\n* Patients with prior history of hepatocellular carcinoma.\n* Patients coinfected with HIV or HCV.\n* Patients with any malignancies.\n* Pregnant and lactating women.","65 Years",{"count":163,"type":20},44,[165],"PHASE2","This study aims to investigate the possible safety and efficacy of Zinc sulphate as antifibrotic agent in chronic HBV patient receiving antiviral therapy.",[168,27],"Liver Fibroses","2025-08-20",{"date":171,"type":37},"2025-08-28",{"date":173,"type":20},"2025-09-01",{"date":175,"type":20},"2026-09",{"name":177,"class":44},"Tanta University",{"id":179,"slug":180,"hasResults":11,"nctId":181,"briefTitle":182,"officialTitle":183,"acronym":184,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":187,"conditions":188,"keywords":190,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":195,"lastUpdatePostDateStruct":196,"startDateStruct":198,"completionDateStruct":200,"leadSponsor":202,"locationsCount":204},"100572103","occult-hepatitis-b-virus-infection-and-hbv-reactivation-after-switching-to-long-acting-therapy-in-patients-with-hiv-1-100572103","NCT06728917","Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients With HIV-1","Occult Hepatitis B Virus Infection and HBV Reactivation After Switching to Long Acting Therapy in Patients Living With HIV-1","OBILART","Inclusion Criteria:\n\n* Age \\> 18 years\n* Informed consent to participate in the study\n* HIV infection\n* Stable antiretroviral therapy (ART) in the six months prior to enrollment without virological failure defined by HIV-RNA\\>50 copies\u002FmL in at least two consecutive determinations\n* Positive HBV anti-core antibodies (HBcAb) in the absence of hepatitis B surface antigen (HBsAg)\n* Absence of mutations associated with resistance to integrase inhibitors (INSTIs) and reverse transcriptase inhibitors (NNRTIs) by HIV genotypic resistance testing\n* CD4 Nadir \\>200 cells\u002Fmm3\n\nExclusion Criteria:\n\n* Any contraindications to the use of one or more long-acting drugs\n* Non-expression or withdrawal of informed consent to participate in the study\n* Pregnancy\n* Lack of HIV genotypic resistance testing\n* Virological failure (HIV-RNA \\>50 copies\u002FmL in at least 2 consecutive determinations) in the 6 months prior to enrollment\n* Therapeutic interruptions in the six months prior to enrollment, excluding interruptions lasting less than a month due to tolerability\n* CD4 Nadir =\\\u003C200 cells\u002Fmm3\n* Presence of biochemical signs of hepatocellular necrosis (AST, ALT \\> normal values as indicated in laboratory tests).\n* Cirrhosis and\u002For fibrosis score \\>F3 assessed by transient elastography (FibroScan).",{"count":19,"type":20},"The primary objective of the present project will be to investigate the risk of HBV reactivation (from virological reactivation to overt HBV infection) in HIV-1 carriers with occult HBV infection (OBI, is characterized by the absence of surface antigenemia, HBsAg negativity, with the presence of HBV-core antibody, HBcAb) and switching from antiretroviral therapy (ART) including nucleos(t)ides to long-acting formulation.",[27,189],"HIV Infection",[191,192,193,194],"Occult hepatitis B virus infection","long acting therapy","people living with HIV-1","HBV reactivation","2024-12-10",{"date":197,"type":37},"2024-12-11",{"date":199,"type":20},"2025-01-20",{"date":201,"type":20},"2025-11-30",{"name":203,"class":44},"IRCCS San Raffaele",3,{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":161,"enrollmentInfo":212,"targetDuration":4,"studyType":21,"phases":214,"briefSummary":216,"conditions":217,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":219,"lastUpdatePostDateStruct":220,"startDateStruct":222,"completionDateStruct":224,"leadSponsor":226,"locationsCount":229},"100566897","phase-1-study-of-epi-003-in-select-nucleostide-analogue-treated-chronic-hepatitis-b-patients-100566897","NCT06661148","Study of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients","A Phase 1, Open-Label, 2-Part Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of EPI-003 in Select Nucleos(t)Ide Analogue-Treated, Chronic Hepatitis B Patients.","Inclusion Criteria:\n\n1. Aged 18 to 65 years (inclusive) at the time of signing the informed consent.\n2. Body mass index (BMI) ≥ 18 kg\u002Fm2 and ≤ 35 kg\u002Fm2 at Screening, and body weight of ≤ 120 kg.\n3. Chronic HBV infection for ≥ 6 months prior to Screening (eg, positive for serum HBsAg, HBV DNA, HBeAg for ≥ 6 months ) or serum immunoglobulin M (IgM) anti-HBc (hepatitis B core antibody) negative at Screening; AND Baseline HBsAg positive at Screening.\n4. Has received treatment with a NA (entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide) as a stable dose for ≥ 6 months before Screening and plans to continue at the same dose level for the duration of the study. Participants may be on other NAs but require Sponsor approval before enrolment.\n5. HBV DNA \\\u003C LLOQ (according to local guidelines) for ≥ 6 months and at Screening\n6. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2 × upper limit of normal (ULN) at Screening.\n7. Able and willing to attend the necessary visits to the study site.\n8. Able and willing to provide written informed consent after the nature of the study has been explained and prior to the commencement of any study procedures.\n\nExclusion Criteria:\n\n1. Evidence or history of liver disease of non-HBV aetiology.\n2. Previous history or current diagnosis of significant liver fibrosis or cirrhosis\n3. Liver ultrasound or other imaging with findings suggestive of HCC at any time.\n4. Participants with serum alpha-fetoprotein (AFP) ≥ 200 ng\u002FmL at Screening.\n5. Positive test result for HIV-1 or HIV-2 that suggests a concurrent infection at Screening.\n6. History of acute febrile illness, symptomatic viral, bacterial, or fungal infection within 1 week before Day 1.\n7. History of receiving HBV vaccine or other HBV-targeted therapeutic within the 6 months before Day 1.\n8. Previous treatment with an HBV-targeted treatment other than NAs within the 6 months before Day 1 or planned use during the study.\n9. Any of the laboratory values at Screening (Screening laboratory tests may be repeated once for values thought to be erroneous OR not clinically significant as per the PI):\n10. Immunodeficient or autoimmune conditions due to disease.\n11. Chronic treatment with immunosuppressants.\n12. Any history of unexplained blackouts, fainting episodes, significant arrythmias, clinically significant abnormality of ECG, marked QT abnormalities, or any known risk factors for Torsade de Points\n13. History of anaphylaxis, hypersensitivity, or significant drug allergies.\n14. Received any antiplatelet or antithrombotic therapy.\n15. History of thrombophilia or history of a positive genetic test for Factor V Leiden and\u002For prothrombin 20210.\n16. Known or suspected intolerance or hypersensitivity to the IP components.\n17. Have received any other IP within 30 days or 5 half-lives of Day 1.\n18. Have received any vaccination within 14 days prior to Day 1 or vaccination planned for 3 months following administration of IP.\n19. Received any medications or other treatments that may adversely affect the immune system.\n20. Excess alcohol consumption within 3 months of Screening.\n21. Significant drug abuse\u002Faddiction within 3 months of Screening.\n22. Any safety concern or personal condition that is inappropriate for study participation per the Investigator's judgement.",{"count":213,"type":20},36,[215],"PHASE1","This study is an open-label, 2-Part (Single Ascending Dose \\[Part 1\\] And Dose Expansion) study that will evaluate the safety of EPI-003 administered to patients with chronic infection with HBV (CHB). EPI-003 is a liver-targeted antiviral therapeutic for intravenous (IV) injection that is capable of precise epigenetic modifications of the HBV genome without causing mutations in the gene sequence itself. This study is designed to determine the safety and pharmacokinetic (PK) and pharmacodynamic (PD) profile of EPI-003 in this patient population.",[218,27],"Chronic Hepatitis B","2024-10-25",{"date":221,"type":37},"2024-10-28",{"date":223,"type":20},"2024-12-01",{"date":225,"type":20},"2027-06-30",{"name":227,"class":228},"Epigenic Therapeutics, Inc","INDUSTRY",4]